Literature DB >> 12673200

Delineation of the domains required for physical and functional interaction of p14ARF with human topoisomerase I.

Olivier Ayrault1, Ayrault Olivier, Lucie Karayan, Karayan Lucie, Jean-François Riou, Riou Jean-François, Christian-Jacques Larsen, Larsen Christian-Jacques, Paule Séité, Séité Paule.   

Abstract

We recently reported an interaction between the p14(ARF) protein and human topoisomerase I (Topo I) resulting in the stimulation of the relaxation activity of Topo I. Our data showed that the complex between the two proteins was located within the nucleolus. In the present work, we have investigated the regions of p14(ARF) involved in this interaction by using targeted point mutagenesis and deletion mutants. A region encompassing exon 2-encoded sequence was required for physical binding of p14(ARF) to Topo I as well as for stimulatory activity of the enzyme. Exon 1 beta-encoded segment was not implicated in the interaction. Moreover, among p14(ARF) point mutants selected for their high conservation among different mammalian species, mutant p14(ARF) (RR87, 88AA) did not stimulate Topo I in spite of its association with the enzyme, suggesting its direct implication in the functional activity of ARF. In contrast, one mutant, p14(ARF) (R71A), was more efficient than wild-type protein to activate Topo I, suggesting that this residue is a key element to modulate Topo I activity. Finally, only ARF-Topo I complexes containing p14(ARF) exon 2 segment were found to be localized in the nucleolus, suggesting that this subnuclear location is linked to the biological function of the ARF-Topo I complex.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12673200     DOI: 10.1038/sj.onc.1206214

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines.

Authors:  Keya Bandyopadhyay; Ruth A Gjerset
Journal:  Biochemistry       Date:  2011-01-12       Impact factor: 3.162

Review 2.  DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer.

Authors:  Ruth A Gjerset
Journal:  J Mol Histol       Date:  2006-07-20       Impact factor: 2.611

3.  PRMT1 promotes the tumor suppressor function of p14ARF and is indicative for pancreatic cancer prognosis.

Authors:  Antje Repenning; Daniela Happel; Caroline Bouchard; Marion Meixner; Yesim Verel-Yilmaz; Hartmann Raifer; Lena Holembowski; Eberhard Krause; Elisabeth Kremmer; Regina Feederle; Corinna U Keber; Michael Lohoff; Emily P Slater; Detlef K Bartsch; Uta-Maria Bauer
Journal:  EMBO J       Date:  2021-05-17       Impact factor: 11.598

4.  The p14ARF alternate reading frame protein enhances DNA binding of topoisomerase I by interacting with the serine 506-phosphorylated core domain.

Authors:  Keya Bandyopadhyay; Pingchuan Li; Ruth A Gjerset
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

5.  CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity.

Authors:  Keya Bandyopadhyay; Pingchuan Li; Ruth A Gjerset
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

6.  Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer.

Authors:  Liqiang Xi; Andrew Feber; Vanita Gupta; Maoxin Wu; Andrew D Bergemann; Rodney J Landreneau; Virginia R Litle; Arjun Pennathur; James D Luketich; Tony E Godfrey
Journal:  Nucleic Acids Res       Date:  2008-10-16       Impact factor: 16.971

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.